With our publication we proved that chemotherapy may be effective in patients with this type of thyroid carcinoma. In about half of patients tumor size decreased at least for 50%. Till now it was believed that this type of thyroid carcinoma is resistant to chemotherapy.
COBISS.SI-ID: 1181307
78 patients were treated by gemcitabine 250 mg/m2 in a 6-h infusion on days 1 and 8 and cisplatin at 75 mg/m2 on day 2 of a 3-week cycle for four cycles, followed by two additional cycles without cisplatin. 5% of patients showed a complete response and 45% showed a partial response. Minimal response or stable disease was seen in 45%, whereas only 5% patients progressed during treatment. Because of the acceptable toxicity, remarkable activity, and reasonable cost, this treatment should be further explored.
COBISS.SI-ID: 1199995
A chart review of 388 patients with follicular neoplasm, who were surgically treated between 1988 and 2009, was performed. The histopathological diagnoses were carcinoma, adenoma, and benign goiter in 127 (33%), 126 (32%), and 135 (35%) patients, respectively. Among 127 patients with carcinoma 71 patients had follicular variant of papillary carcinoma, 33 follicular carcinoma, 17 patients classic type of papillary carcinoma, 3 Hürthle cell carcinoma, two poorly differentiated carcinoma and one patient trabecular variant of papillary carcinoma.The independent predictors of malignancy as shown by multivariate logistic regression were age of patients, solitary tumor and Tg concentration. Carcinoma was more common in patients younger than 45 years, with solitary tumor and with preoperative serum Tg concentration more than 400 ng/ml.
COBISS.SI-ID: 1120891
Eight predictive models assessing the risk of non-sentinel noden (non-SN) involvement in patients with breast cancer sentinel node (SN) metastasis were tested in a multi-institutional setting. Data of 200 consecutive patients with metastatic SNs and axillary lymph node dissection from each of the 5 participating centres were entered into the selected non-SN metastasis predictive tools. There were significant differences between centres in the distribution of most parameters used in the predictive models. There were also significant differences in the proportion of cases classified as having low risk of non-SN metastasis. Each predictive tool used in clinical practice for patient and physician decision on further axillary treatment of SN-positive patients may require individual institutional validation; such validation may reveal different predictive tools to be the best in different institutions.
COBISS.SI-ID: 1291899